Preparation of a pure autologous biodegradable fibrin matrix for tissue engineering

被引:45
作者
Haisch, A
Loch, A [1 ]
David, J
Pruss, A
Hansen, R
Sittinger, M
机构
[1] Humboldt Univ, Fac Med, Dept Otorhinolaryngol Head & Neck Surg, Berlin, Germany
[2] Humboldt Univ, Fac Med, Tissue Engn Lab, Berlin, Germany
[3] Tech Univ Berlin, Biotechnol Fac, Berlin, Germany
[4] Humboldt Univ, Fac Med, Inst Transfus Med, Berlin, Germany
[5] Humboldt Univ, Fac Med, Inst Lab Med & Pathobiochem, Berlin, Germany
[6] Humboldt Univ, Fac Med, Dept Rheumatol, Berlin, Germany
[7] German Rheumatism Res Ctr, Berlin, Germany
关键词
tissue engineering; autologous fibrinogen; thrombin; matrix;
D O I
10.1007/BF02344876
中图分类号
TP39 [计算机的应用];
学科分类号
081203 ; 0835 ;
摘要
Parallel to the growing role of tissue engineering, the need for cell embedding materials, which allow cells to stabilise in a three-dimensional distribution, has increased. Although several substances have been tested, fibrin is thus far the only one that permits the clinical application of cultured tissue. To date, autologous fibrinogen has usually been polymerised with bovine thrombin, which can cause severe immunological side effects. The objective of this study was to explore the practicability of obtaining autologous thrombin from a single patient in an adequate concentration and amount, Fibrinogen was cryoprecipitated from 200 mi of freshly-frozen plasma. Thrombin was isolated from the supernatant through ion-exchange chromatography. The thrombin was first bound to Sephadex A-50 and then eluated using 2ml of a salt buffer (2.0M NaCl in 0.015M trisodiumcitrate, pH 7.0). The activity of the thrombin (51 NIH ml(-1) to 414 NIH ml(-1)) reached levels comparable to those in commercially available fibrin glues (4-500 NIH ml(-1)). The study has shown that if is possible to obtain a sufficient amount of autologous thrombin from a single donor to create a fibrin matrix of high efficiency without the risk of immunological and infectious side effects.
引用
收藏
页码:686 / 689
页数:4
相关论文
共 22 条
[11]   CONTRIBUTIONS TO OPTIMAL USE OF HUMAN-BLOOD .6. MODIFICATION OF METHOD TO PREPARE PROTHROMBIN COMPLEX ON A LARGE-SCALE [J].
HEYSTEK, J ;
MAIERVANDERZANDE, GM ;
BRUMMELHUIS, HGJ ;
KRIJNEN, HW .
VOX SANGUINIS, 1975, 29 (03) :177-183
[12]  
KJAERGARD HK, 1997, CARDIOVASC ENG, V2, P204
[13]  
Muntean W, 1997, THROMB HAEMOSTASIS, V77, P1223
[14]  
NICHOLS WL, 1993, BLOOD, V82, P59
[15]   Fibrin sealant: Scientific rationale, production methods, properties, and current clinical use [J].
Radosevich, M ;
Goubran, HA ;
Burnouf, T .
VOX SANGUINIS, 1997, 72 (03) :133-143
[16]   Development of in vitro model systems for destructive joint diseases - Novel strategies for establishing inflammatory pannus [J].
Schultz, O ;
Keyszer, G ;
Zacher, J ;
Sittinger, M ;
Burmester, GR .
ARTHRITIS AND RHEUMATISM, 1997, 40 (08) :1420-1428
[17]  
SEELICH T, 1981, NEUES FIBRINOGEN FIB, P199
[18]   Tissue engineering and autologous transplant formation: Practical approaches with resorbable biomaterials and new cell culture techniques [J].
Sittinger, M ;
Bujia, J ;
Rotter, N ;
Reitzel, D ;
Minuth, WW ;
Burmester, GR .
BIOMATERIALS, 1996, 17 (03) :237-242
[19]  
Spilker G, 1996, Langenbecks Arch Chir Suppl Kongressbd, V113, P1149
[20]  
TANKA K, 1990, Patent No. 4923815